SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price jumped following news that CEO Elon Musk purchased a significant amount of shares, his first open-market buy since 2020. The community is discussing whether this purchase signals a short squeeze to $500 and how it impacts the stock's technical analysis. Many view this as a bullish sign, while some remain skeptical, citing concerns about valuation and Musk's overall strategy.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to a recent surge following positive trial results for its stroke therapy, with community members debating whether to hold for a potential FDA submission catalyst or take profits amidst concerns of manipulation and past reverse splits. The stock's low float is fueling discussions about a potential short squeeze, while some caution against a possible offering. The community is closely watching for news that could drive the price higher, as well as the company's next move.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around ATYR as traders await the release of Phase 3 trial data, expected mid-September, with the community buzzing about potential data leaks and speculating on the timing of the results. Community members are weighing bullish and bearish perspectives, debating the likelihood of trial success, and analyzing the potential for a short squeeze. With a binary event on the horizon, ATYR is seeing increased volatility and high options premiums, driving significant conversation among investors.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies behind the project's resilience and upcoming developments, including a Bifinance listing and airdrop. Community members highlight the project's organic growth, transparency, and active development team. Bullish sentiment is high, with many anticipating new ATHs and increased exposure for this Solana-based token.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to its recent merger with Strive and a planned pivot towards Bitcoin asset management, creating excitement around a potential short squeeze. Some platforms are experiencing trading halts due to the CUSIP change, while community members debate holding strategies amidst high short interest and borrow fees. The stock's association with figures like Vivek Ramaswamy is also fueling speculation and interest.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to Needham's raised price target and overall excitement in the quantum computing sector, sparking discussions about its potential and possible acquisitions. Community members debate the company's valuation, long-term prospects, and potential to become the "next NVDA", while also discussing upcoming catalysts like the analyst day and potential government contracts. The stock's breakout and trading volume are also contributing to the increased attention.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as retail investors anticipate new peaks, with community members actively discussing potential price movements and key resistance levels. The stock is also gaining attention due to its participation in the White House's eVTOL pilot program and speculation around defense contracts. Community sentiment suggests anticipation for a potential squeeze, with some expressing frustration over the stock's performance compared to sector peers.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending due to positive momentum, with the stock hitting new 52-week highs and breaking through resistance levels, fueling bullish sentiment. The community is discussing potential for further gains, eyeing targets like $60 and beyond, driven by the anticipation around the Neutron rocket and recent mission successes. Some are noting increased call option activity and institutional investment as potential drivers for continued upward movement.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is trending as traders discuss potential downside for Tesla (TSLA) amid ongoing debate around its valuation, sales, and the impact of Elon Musk's actions. Community members are actively strategizing entry points and discussing potential profit targets, considering both technical analysis and broader market sentiment. Some traders mention potential short-term gains while others suggest Tesla fundamentals do not justify the current market value.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss the potential impact of a recent real-world tragedy, with some speculating it could drive increased traffic to the platform amid broader conversations around free speech. Community members are also weighing in on the company's fundamentals, potential catalysts like the upcoming wallet launch, and the proposed acquisition of Northern Data. Additionally, there's discussion around the high short interest and its potential to fuel a squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sellas Life Sciences Group, Inc. (SLS) on Thursday announced that an institutional investor has exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025.In consideration for the immediate exercise of the warrants in full, the investor will receive new unregistered warrants in a private placement to purchase up to 19.69 million shares of its common stock at an exercise price of $1.88. These warrants will be exercisable immediately and will expire five years and six months from the date of issuance, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-23-6-Million-in-Gross-Proceeds/default.aspx">said</a>.The closing of the transaction is expected to occur on or about Sept. 12, 2025, subject to satisfaction of customary closing conditions.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for cancer. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types. The company is also developing SLS009 in the treatment of Acute Myeloid Leukemia. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels. Shares of the company were fell over 2% at the time of writing.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_33_53_PM_png_42e9b0a3c2.webp" alt="SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded skeptical about the new warrants.<stembedurl>https://stocktwits.com/RandomInvestor777/message/628334051</stembedurl>Another user noted they have added to their position.<stembedurl>https://stocktwits.com/SomedayisNow/message/628326459</stembedurl>SLS stock is up 76% this year and approximately 39% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wolfpack-research-reveals-short-position-in-faraday-future/chwNmHARdvm">Wolfpack Research Reveals Short Position In EV Maker Faraday Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock.

Equity

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock at an exercise price of $1.88. 


SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful...

SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Sellas Life Sciences files $200M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sellas Life Sciences files to sell 13.03M shares of common stock for holders

Sellas Life Sciences reports 2023 EPS ($1.34), consensus ($1.08)

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLS SELLAS Life Sciences Group Inc